For example, in breast and colon cancer and melanoma models, by reprograming the tumor-associated macrophage population to a proinflammatory phenotype and increasing tumor immunogenicity, anti-MARCO monoclonal antibodies can inhibit tumor progression [30]. The gene discussed is MARCO; the disease is neoplasm.